In the context of MM, the efficacy of PD-1/PD-L1 blockade may also be favored by the use of tumor vaccines, which can be administered for the expansion of MM-reactive T-cell clones and, as a consequence, for the activation with checkpoint blockade (20, 36). This evidence concerns the gene PDCD1 and Miyoshi myopathy.